[212Pb]Pb-DOTAM-MAM279

N/A

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug Name[212Pb]Pb-DOTAM-MAM279
Drug Alias Name[212Pb]Pb-MP0712[212Pb]Pb-MP-0712
ClassificationRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsNeuroendocrine Carcinoma of LungGastroenteropancreatic neuroendocrine tumorSmall Cell Lung Carcinoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMolecular Partners Ag
China Registration ClassN/A

Develop Information

Active CompaniesOrano Med LlcMolecular Partners Ag
Inactive CompaniesN/A
Active IndicationsNeuroendocrine Carcinoma of LungGastroenteropancreatic neuroendocrine tumorSmall Cell Lung Carcinoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A